08:21 AM EDT, 06/23/2025 (MT Newswires) -- Forte Biosciences ( FBRX ) reported "positive" data Monday from a phase 1b trial of lead program FB102 to treat celiac disease.

The biopharmaceutical company said the study assessed morphologic and inflammatory endpoints along with gluten-challenge induced symptoms.

Chief Executive Paul Wagner said the results are "very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes."

Shares of Forte Biosciences ( FBRX ) climbed 33% in recent premarket activity.